PPIDT00102
Drug Information
| Name | Eculizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB01257 |
| Type | biotech |
| Indication | Eculizumab is indicated in the US to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD).[L6916,A2246] It is also indicated in EU to treat PNH in both adult and pediatric patients.[L46866] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intravenous |
300 mg
|
| Injection, solution, concentrate | — |
300 mg/30ml
|
| Solution, concentrate | Intravenous |
1000000 mg
|
| Injection, solution, concentrate | Intravenous |
300 mg/30mL
|
| Injection, solution, concentrate | Intravenous; Parenteral |
300 MG
|
| Solution | Intravenous |
10 mg / mL
|
| Solution, concentrate | Intravenous |
300 mg
|
| Solution, concentrate | Intravenous |
30000000 mg
|
| Injection, solution, concentrate | Intravenous |
10 mg/ml
|
| Injection, solution, concentrate | Parenteral |
300 mg/30ml
|
| Solution | Intravenous |
300 mg
|